A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Status:
Recruiting
Trial end date:
2022-11-18
Target enrollment:
Participant gender:
Summary
This study will evaluate if participants treated with ofatumumab 20 mg subcutaneous (s.c.)
administered once monthly can develop an adequate immune response to the COVID-19 mRNA
vaccine compared to participants on an interferon or glatiramer acetate.